Business Description
![Ionis Pharmaceuticals Inc Ionis Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C00000BLV.png?14)
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Compare
Compare
Traded in other countries / regions
IONS.USA0JDI.UKISI.GermanyIONS.Mexico IPO Date
1991-05-17Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.53 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 4.87 | |||||
Debt-to-EBITDA | -5.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.25 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.7 | |||||
3-Year EBITDA Growth Rate | -27.4 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year FCF Growth Rate | -298.6 | |||||
3-Year Book Growth Rate | -20.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 12.9 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.2 | |||||
9-Day RSI | 57.06 | |||||
14-Day RSI | 51.28 | |||||
6-1 Month Momentum % | -15.53 | |||||
12-1 Month Momentum % | 2.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.37 | |||||
Quick Ratio | 7.28 | |||||
Cash Ratio | 6.73 | |||||
Days Inventory | 969.73 | |||||
Days Payable | 581.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -4.15 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.72 | |||||
Operating Margin % | -50.1 | |||||
Net Margin % | -49.54 | |||||
FCF Margin % | -44.68 | |||||
ROE % | -100.54 | |||||
ROA % | -13.23 | |||||
ROIC % | -75.58 | |||||
ROC (Joel Greenblatt) % | -112.19 | |||||
ROCE % | -11.06 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.21 | |||||
PB Ratio | 19.16 | |||||
Price-to-Tangible-Book | 19.21 | |||||
EV-to-EBIT | -17.37 | |||||
EV-to-Forward-EBIT | -9.02 | |||||
EV-to-EBITDA | -18.87 | |||||
EV-to-Forward-EBITDA | -9.29 | |||||
EV-to-Revenue | 6.34 | |||||
EV-to-Forward-Revenue | 8.38 | |||||
EV-to-FCF | -14.25 | |||||
Price-to-Projected-FCF | 13.68 | |||||
Price-to-Median-PS-Value | 0.65 | |||||
Earnings Yield (Greenblatt) % | -5.76 | |||||
FCF Yield % | -6.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 716.533 | ||
EPS (TTM) (€) | -2.476 | ||
Beta | -0.3 | ||
Volatility % | 28.85 | ||
14-Day RSI | 51.28 | ||
14-Day ATR (€) | 0.718755 | ||
20-Day SMA (€) | 34.955 | ||
12-1 Month Momentum % | 2.98 | ||
52-Week Range (€) | 33.27 - 48.76 | ||
Shares Outstanding (Mil) | 145.97 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ionis Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(STU:ISI)'s stock price today?
The current price of STU:ISI is €36.11. The 52 week high of STU:ISI is €48.76 and 52 week low is €33.27.
When is next earnings date of Ionis Pharmaceuticals Inc(STU:ISI)?
The next earnings date of Ionis Pharmaceuticals Inc(STU:ISI) is 2024-08-09 Est..
Does Ionis Pharmaceuticals Inc(STU:ISI) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(STU:ISI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |